Marker Therapeutics Files 8-K

Ticker: MRKR · Form: 8-K · Filed: Aug 26, 2025 · CIK: 1094038

Marker Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyMarker Therapeutics, Inc. (MRKR)
Form Type8-K
Filed DateAug 26, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, financials, corporate-filing

TL;DR

Marker Therapeutics filed an 8-K on 8/26/25. Check financials & disclosures.

AI Summary

Marker Therapeutics, Inc. filed an 8-K on August 26, 2025, reporting on Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as TAPIMMUNE INC., is incorporated in Delaware and headquartered in Houston, Texas.

Why It Matters

This filing provides an update on Marker Therapeutics' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, indicating standard corporate reporting rather than a specific event with immediate high risk.

Key Numbers

  • 001-37939 — Commission File Number (Identifier for the company's SEC filings)
  • 45-4497941 — IRS Employer Identification No. (Tax identification number for the company)

Key Players & Entities

  • Marker Therapeutics, Inc. (company) — Registrant
  • TAPIMMUNE INC. (company) — Former company name
  • Delaware (jurisdiction) — State of incorporation
  • Houston, Texas (location) — Business address
  • August 26, 2025 (date) — Date of report

FAQ

What specific financial statements are being disclosed in this 8-K filing?

The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the excerpt.

What is the primary purpose of this 8-K filing?

The primary purpose is for Regulation FD Disclosure and to report on Financial Statements and Exhibits, as indicated by the 'ITEM INFORMATION' section.

When was Marker Therapeutics, Inc. previously known by another name?

Marker Therapeutics, Inc. was formerly known as TAPIMMUNE INC., with name changes noted on June 29, 2017, and June 28, 2007.

Where is Marker Therapeutics, Inc. headquartered?

The company is headquartered in Houston, Texas, with its business address listed as 2450 Holcombe Blvd, TMC Partners Office 1.311.

What is the fiscal year end for Marker Therapeutics, Inc.?

The fiscal year end for Marker Therapeutics, Inc. is December 31 (1231).

Filing Stats: 619 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2025-08-26 07:16:20

Key Financial Figures

  • $0.001 — h registered Common Stock, par value $0.001 per share MRKR The Nasdaq Stock Mar

Filing Documents

01. Regulation

Item 7.01. Regulation FD Disclosure. On August 26, 2025, Marker Therapeutics, Inc. (the " Company ") issued a press release announcing the progress and clinical observations from the Company's Phase 1 APOLLO study. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. In addition, on August 26, 2025, the Company updated its corporate presentation, which is available through the Company's website and a copy of which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K. The Company will also host a webcast discussing the results from the Company's APOLLO study. The webcast presentation is attached hereto as Exhibit 99.3. The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1, 99.2 and 99.3) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, dated August 26, 2025. 99.2 Corporate Presentation, dated August 26, 2025. 99.3 Webcast Presentation, dated August 26, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Marker Therapeutics, Inc. Dated: August 26, 2025 By: /s/ Juan Vera Juan Vera President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.